Skip to main content
. 2019 Apr 28;2019:5269062. doi: 10.1155/2019/5269062

Figure 2.

Figure 2

Overlay of Kaplan–Meier curves indicating the probability for OS (OS) for advanced melanoma patients treated with anti-PD1 as first-line immunotherapy, representing (1) the historical probability for OS for patients diagnosed with stage IV melanoma prior to the availability of life-prolonging medical treatment options (dashed black line) [1]; (2) a pooled OS analysis including individual patient survival data from 1,861 patients with metastatic melanoma from 12 clinical investigations of ipilimumab and 2,985 patients with metastatic melanoma from a US ipilimumab EAP (total n = 4,846) (blue line) [9]; (3) CA209-003 phase I clinical trial with nivolumab for pretreated advanced melanoma patients (dark green line) [11]; (4) treatment naïve patients (n: 151) treated in the Keynote-001 clinical trial with pembrolizumab (light green line) [10]; (5) treatment naïve patients (n, 368) from the Keynote-006 trial (red line) [13]; (6) nivolumab treated patients with BRAF V600 wild-type melanoma (n, 210) from the Checkmate-066 trial (blue line) [73]; (7) nivolumab monotherapy treated patients (n, 314) from the CheckMate-067 trial (pink line) [72]; (8) nivolumab plus ipilimumab treated patients (n, 316) from the CheckMate-067 trial (orange line) [72].